secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harvard Apparatus Regenerative Technology, Inc. (HRGN)
CIK:        0001563665
Form:       8-K
Filed at:   2023-07-20T23:59:59+00:00
Accession:  0001493152-23-025017
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harvard Apparatus Regenerative (fka Biostage) trades under HRGN; FDA clears 10-patient phase 1 esophageal study
--------------------------------------------------------------------------------

- Name changed from Biostage to Harvard Apparatus Regenerative Technology; new ticker HRGN on OTCQB effective July 20, 2023.
- FDA approved a 10-patient phase 1 study for esophageal implant; enrollment opened.
- Company plans to launch anti-aging business in China; expects it to be cash flow positive in fiscal 2023.
- Launched new website www.hregen.com to highlight regenerative technology and anti-aging strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563665/000149315223025017/0001493152-23-025017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563665/000149315223025017/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-025017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer